ClinicalTrials.gg
CompletedNCT03287674Updated Mar 1, 2023Results posted

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

A Phase 1/2 interventional study of Cyclophosphamide and Fludarabine in Metastatic Ovarian Cancer, sponsored by Inge Marie Svane. Completed at 1 site in Denmark. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-01.

Sponsored by Inge Marie Svane · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 104 studies in Ovarian Neoplasms with a site in Denmark — 17 open to participants now, 27 under way, 15 of them phase 3. Ovarian Neoplasms · Denmark.

Enrollment
85th of 90
7 · median 237
Started
2017
with 4 others
Phase 1/2
13 of 104
1 open now
Registered
61st of 104
by date
Lead sponsor
3 of 104
Inge Marie Svane

Among the 104 studies in Ovarian Neoplasms with a site in Denmark, this one is the 85th largest by enrollment of the 90 interventional ones that give a count, is one of 5 that started in 2017, is one of 13 in phase 1/2, and was the 61st registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

17 of the 104 studies in Ovarian Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Ovarian Neoplasms with a site in Denmark, or all of them as a file.
02

Study summary

Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma. Recently, the investigators have completed a pilot study treating 6 patients with metastatic ovarian cancer. The TILs are isolated from patients own tumor tissue followed by in vitro expansion and activation for around 4-6 weeks. Before TIL infusion the patients receive 1 week of preconditioning chemotherapy with cyclophosphamide and fludarabine. After TIL infusion Interleukin-2 is administered to support T cell activation and proliferation in vivo.

The investigators recent pilot study has shown TIL therapy in patients with metastatic ovarian cancer to be feasible and tolerable. Mainly transient clinical responses where observed and therefore the investigators plan to combine TIL therapy with checkpoint inhibitors to potentially increase the clinical effect.

Read the detailed description

Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma. Recently, the investigators have completed a pilot study treating 6 patients with metastatic ovarian cancer. The TILs are isolated from patients own tumor tissue followed by in vitro expansion and activation for around 4-6 weeks. Before TIL infusion the patients receive 1 week of preconditioning chemotherapy with cyclophosphamide and fludarabine. After TIL infusion Interleukin-2 is administered to support T cell activation and proliferation in vivo.

The investigators recent pilot study has shown TIL therapy in patients with metastatic ovarian cancer to be feasible and tolerable. Mainly transient clinical responses where observed and therefore the investigators plan to combine TIL therapy with checkpoint inhibitors to potentially increase the clinical effect.

Objectives:

To evaluate safety and feasibility when treating patients with metastatic ovarian cancer with ACT with TILs in combination with checkpoint inhibitors.

To evaluate treatment related immune responses To evaluate clinical efficacy

Design:

Patients will be screened with a physical exam, medical history, blood samples and ECG.

Patients will be treated with one dose of Ipilimumab 14 days before undergoing surgery to harvest tumor material for TIL production. Patients is admitted on day -8 in order to undergo lymphodepleting chemotherapy with cyclophosphamide and fludara starting day -7. On day -2 patients will start treatment with Nivolumab every 2 weeks for a total of 4 doses to increase the activity of the infused TIL product.

On day 0 patients receive TIL infusion and shortly after starts IL-2 stimulation with a daily subcutaneous dose for a total of 14 days.The patients will followed until progression or up to 5 years.

03

Conditions studied

  • Metastatic Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Only patients within the Danish healthcare system are eligible for enrollment.

Inclusion criteria

Inclusion Criteria:

  • Histological proven advanced ovarian-, fallopian tube or primary peritoneal cancer with the possibility of surgical removal of tumor tissue of > 1 cm3.
  • Progressive or recurrent resistant disease after platin-based chemotherapy (platinum resistant) or progressive or recurrent disease after or additional chemotherapy.
  • Age: 18 - 70 years.
  • performance status of ≤1 (Appendix 2).
  • of > 6 months.
  • At least one measurable parameter in accordance with 1.1 -criteria's.
  • No significant toxicities or side effects from previous treatments, except sensoric- and motoric neuropathy and/or alopecia
  • Sufficient renal, hepatic and hematological function
  • Men and women in the fertile age must use effective . This applies from inclusion and until 6 months after treatment.
  • Able to comprehend the information given and willing to sign

Exclusion criteria

Exclusion Criteria:

  • Other , unless followed for ≥ 5 years with no sign of disease
  • Known to one of the active drugs or one or more of the .
  • Severe medical or psychiatric conditions
  • \< 70 ml/min. In selected cases it can be decided to include a patient with a \< 70 ml/min with the use of a reduced dose of chemotherapy.
  • Acute/chronic infection with , hepatitis, syphilis among others.
  • Severe allergies or previous anaphylactic reactions.
  • Active disease
  • Pregnant women and women breastfeeding.
  • Need for treatment e.g. or methotrexate. In selected cases a systemic dose of ≤10 mg prednisolone or a transient planned treatment that can be stopped before TIL therapy can be tolerated.
  • Simultaneous treatment with other experimental drugs.
  • Simultaneous treatment with other systemic anti-cancer treatments.
  • Patients with active and uncontrollable hypercalcaemia.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Patient group

    All patients receive the same treatment. All patients are treated with one dose of Ipilimumab 14 days prior to surgical removal of tumor tissue for TIL expansion. Hospitalization for TIL treatment is approximately 3 weeks. The patients are admitted to hospital on day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1. The first of 4 doses of Nivolumab is administered on day -2 and every 2 weeks for at total of 4 doses. The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 13. Interleukin-2 is administered as a daily low-dose subcutaneous injection for a total for 14 days.

    Drug: Cyclophosphamide · Drug: Fludarabine · Biological: TIL infusion · Drug: Interleukin-2 · Drug: Ipilimumab · Drug: Nivolumab

Interventions

  • Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.

  • Fludarabine 25 mg/m2 is administered on day -5 to day -1.

    Also known as: Fludarabine phosphate

  • BiologicalTIL infusion

    The maximum number of expanded TILs are infused over 30-45 minutes on day 0.

    Also known as: TILs

  • Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.

    Also known as: IL-2

  • One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.

  • Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Reported Adverse Events by Type

    Determine the safety of TIL therapy in combination with checkpoint inhibitors for patients with ovarian-, fallopian tube or primary peritoneal cancer by reporting adverse events according to CTCAE v. 4.0.

    Time frame: Up to 12 months

Secondary outcomes

  1. Treatment Related Immune Responses

    Ex vivo anti-tumor reactivity of expanded TILs after co-culture measured with flow cytometry.

    Time frame: Until protocol end, until 6 months after TIL infusion

  2. Objective Response Rate

    Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CAT scan: Complete Response (CR) Disappearance of all target lesions (sum of all taget lesions=0) Partial Response (PR) \>=30% decrease (vs baseline) of sum of all target lesions dimension Progressive Disease (PD) new lesions or \>=20% increase (vs smallest sum of target lesions or nadir) Stable Disease (SD) when sum of all target lesions does not qualify for CR/PR/PD

    Time frame: Assessed up to 12 months after therapy.

  3. Overall Survival

    Overall Survival (OS), defined as time from TIL infusion to death

    Time frame: Up to 3 years after TIL infusion

  4. Progression Free Survival

    Progression free survival (PFS): Time from TIL infusion to disease progression, relapse or death due to any cause, which ever comes first, will be used as an event.

    Time frame: Up to 12 months after TIL infusion

07

Results

Posted Mar 22, 2021

Participant flow

Participant flow — Overall Study
MilestoneTIL Treated Patients
Started7
All treated with tils6
Completed6
Not completed1

Outcome measures

PrimaryNumber of Participants With Reported Adverse Events by Type

Determine the safety of TIL therapy in combination with checkpoint inhibitors for patients with ovarian-, fallopian tube or primary peritoneal cancer by reporting adverse events according to CTCAE v. 4.0.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With Reported Adverse Events by Type
ParticipantsTIL Treated Patients
Performance status drop3
Fatigue3
Nausea1
Vomiting1
Diarrhea1
Hyponatremia3
Infection2
Neutropenia6
Trombocytopenia6
Anemia6
Agammaglobulinemia1
Dyspnea1
Fever3
Colitis1
Dry skin1
SecondaryTreatment Related Immune Responses

Ex vivo anti-tumor reactivity of expanded TILs after co-culture measured with flow cytometry.

Time frame:
Until protocol end, until 6 months after TIL infusion
Reported as:
Count of participants · Participants
Treatment Related Immune Responses
ParticipantsPatient Group
Treatment Related Immune Responses6
SecondaryObjective Response Rate

Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CAT scan: Complete Response (CR) Disappearance of all target lesions (sum of all taget lesions=0) Partial Response (PR) \>=30% decrease (vs baseline) of sum of all target lesions dimension Progressive Disease (PD) new lesions or \>=20% increase (vs smallest sum of target lesions or nadir) Stable Disease (SD) when sum of all target lesions does not qualify for CR/PR/PD

Time frame:
Assessed up to 12 months after therapy.
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsTIL Treated Patients
Complete response0
Partial response1
Stabile disease5
Progressive disease0
SecondaryOverall Survival

Overall Survival (OS), defined as time from TIL infusion to death

Time frame:
Up to 3 years after TIL infusion
Reported as:
Median · Days
Overall Survival
DaysTIL Treated Patients
Overall Survival247 (136 to 915)
SecondaryProgression Free Survival

Progression free survival (PFS): Time from TIL infusion to disease progression, relapse or death due to any cause, which ever comes first, will be used as an event.

Time frame:
Up to 12 months after TIL infusion
Reported as:
Median · Days
Progression Free Survival
DaysTIL Treated Patients
Progression Free Survival93 (84 to 342)

Adverse events

Collected over From first therapy and until discontinuation from protocol - up to 12 months after.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TIL Treated Patients6/6 (100%)6/6 (100%)6/6 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventTIL Treated Patients
NeutropeniaBlood and lymphatic system disorders6/6
TrombocytopeniaBlood and lymphatic system disorders6/6
AnemiaBlood and lymphatic system disorders6/6
FatigueGeneral disorders3/6
HyponatremiaRenal and urinary disorders3/6
FeverGeneral disorders3/6
ColitisImmune system disorders1/6
AgammaglobulimiaBlood and lymphatic system disorders1/6
InfectionRenal and urinary disorders1/6
InfectionRespiratory, thoracic and mediastinal disorders1/6
Most frequent other events
Most frequent other events
EventTIL Treated Patients
diarrheaGastrointestinal disorders6/6
nauseaGeneral disorders5/6
DyspneaRespiratory, thoracic and mediastinal disorders4/6
VomitingGastrointestinal disorders3/6
Oral mucositisGastrointestinal disorders3/6
InfectionInfections and infestations2/6
VomitingGastrointestinal disorders2/6
ObstipationGastrointestinal disorders2/6
ThyroiditisEndocrine disorders1/6
Elevated liver enzymesHepatobiliary disorders1/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TIL Treated Patients
<=18 years0
Between 18 and 65 years6
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)TIL Treated Patients
Female6
Male0
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)TIL Treated Patients
Region of Enrollment
Region of Enrollment(participants)TIL Treated Patients
Denmark6
08

Study locations

1 site
  • Center for Cancer Immune Therapy Dept. of Hematology/oncology
    Copenhagen, 2730, Denmark
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jun 2020, 31 months.

Results were first posted in Mar 2021, 9 months after primary completion.

Of 57 non-industry phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 110. This study's 31 months is below that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2017
First posted
Sep 19, 2017
StartActual
Oct 9, 2017
Primary completionActual
Jun 1, 2020
CompletionActual
Jun 1, 2020
Results first posted
Mar 22, 2021
Last update
Mar 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03287674
Lead sponsor
Inge Marie Svane
Responsible party
Inge Marie Svane (M.D., Professor, Herlev Hospital) — Sponsor-investigator
First posted
Sep 19, 2017
Start date
Oct 9, 2017
Primary completion
Jun 1, 2020
Completion
Jun 1, 2020
Results posted
Mar 22, 2021
Last update
Mar 1, 2023

Study contacts

Inge Marie Svane, Prof., M.D.
study director · Center for Cancer Immune Therapy, Depth of Hematology/Oncology, Copenhagen University Hospital Herlev, Herlev Ringvej 75, DK-2730
Magnus Pedersen, M.D.
principal investigator · Center for Cancer Immune Therapy, Depth of Hematology/Oncology, Copenhagen University Hospital Herlev, Herlev Ringvej 75, DK-2730

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Therapeutic Tumor Infiltrating Lymphocytes

Start the discussion